Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study

Table 3 Incidence of adverse events (intention to treat analysis)

	Sodium bicarbonate (N = 92)	Citrate mixture (N = 92)	TaCCi mixture (N = 89)	P
	Patients (%)	Patients (%)	Patients (%)
Newly-onset hemoglobinuria	4 (4.35%)	2 (2.17%)	3 (3.37%)	0.710
Newly-onset nephrolithiasis	1 (1.09%)	2 (2.17%)	1 (1.12%)	0.710
Newly-onset renal cyst	6 (6.98%)	4 (4.65%)	2 (2.44%)	0.383
Newly-onset hypertension	3 (3.26%)	3 (3.26%)	1 (1.12%)	0.785
Skin allergy	0 (0.00%)	1 (1.09%)	0 (0.00%)	0.578
ALT
1–2 × ULN	14 (15.2%)	12 (13.0%)	16 (18.0%)	0.373
2–3 × ULN	1 (1.09%)	0 (0.00%)	2 (2.25%)	0.654
> 3 × ULN	0 (0.00%)	1 (1.09%)	0 (0.00%)	0.350
AST				0.373
1–2 × ULN	4 (4.35%)	7 (7.61%)	10 (11.2%)	0.220
2–3 × ULN	0 (0.00%)	0 (0.00%)	0 (0.00%)	1.00
> 3 × ULN	1 (1.09%)	0 (0.00%)	0 (0.00%)	0.373

ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal, TaCCi mixture tart cherry supplementary citrate mixture

ISSN: 1478-6362